Nelfinavir in HIV-HCV coinfected patients: A 24-month follow-up in a cohort of 82 patients

AIDS Research and Human Retroviruses

Volumn 21, Issue 10, 2005, Pages 841-844

  Poizot Martin, Isabelle ^a,b   Marimoutou, C ^a,b   Drogoul Vey, M P ^a   Vion Dury, F ^a   Frixon Marin, V ^a   Benhaim, S ^a   Poggi, P ^a   Gastaut, J A ^a,b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 31444451798     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.841     Document Type: Article

References (21)

1. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, et al.: HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: Incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003;32: 259-267.
2. Sulkowski MS: Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23:183-194.
3. Kontorinis N and Dieterich D: Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003;5:36-43.
4. Pol S, Lebray P, and Vallet-Pichard A: HIV infection and hepatic enzyme abnormalities: Intricacies of the pathogenic mechanisms. Clin Infect Dis 2004;38(Suppl. 2):S65-S72.
5. Pialoux G, Bonnard P, and Rozenbaum W: Toxicité hépatique des antirétroviraux. Gastroenterol Clin Biol 2003;27:155-158.
6. Vento S, Garafano T, Renzini C, Casali F, and Ferrato T: Concia: Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998;12:116-117.
7. Bonacini M: Liver injury during highly active antiretroviral therapy: The role of hepatitis C coinfection. Clin Infect Dis 2004; 38(Suppl. 2):S104-S108.
8. Sav̀s M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernou A, et al.: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000;44:3451-3455.
9. Javier E, Amador C, Benito C, Fenoll V, and Pasquau F: Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003;14:776-781.
10. Den Brinken M, Wit FW, Wertheim-Van Dillen PM, Jurriaans S, Weel J, Van Leeuwen R, et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV infection. AIDS 2000;14:2895-2902.
11. Bozette SA, Ake CF, TAM HK, Chang SW, and Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348: 702-710.
12. Behrens GMN, Meyer-Olson D, Stoll M, and Schmidt RE: Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. AIDS 2003;17(Suppl. 1):S141-S148.
13. Mary-Krause M, Cotte L, Simon A, Partisani M, and Costagliola D, for the Clinical Epidemiology Group from the French Hospital: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486.
14. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al.: Data Collection on Adverse Events of Anti-HIV Drags (DAD) Study Group: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
15. Murphy RL and Smith WJ: SWITCH IP: Switch studies: A review. HIV Med 2002;3:146-155.
16. Patroni A, Torti C, Tomasoni L, Quiros Roldan E, Bertelli D, Puoti M, et al.: Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: A retrospective longitudinal study. HIV Clin Trials 2002;3: 451-461.
17. Caron M, Auclair M, Sterlingot H, Kornprobst M, and Capeau J: Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003;17:2437-2444.
18. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, et al.: D. A. D. Study Group: Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drags associated with different lipid profiles? J Infect Dis 2004;189:1056-1074.
19. Havlir DV and O'Marro SD: Atazanavir: New option for treatment of HIV infection. Clin Infect Dis 2004;38:1599-1604.
20. Sulkowski MS, Thomas DL, Chaisson RE, and Moore RD: Elevated liver enzymes following initiation of antiretroviral therapy. JAMA 2000;283:2526-2257.
21. S Pol: Prise en charge de l'infection virale C chez les patients coinfectés par le VIH recevant un traitement antirétroviral. Presse Med 2001;30:677-682.